(Q54435289)

29 May 2018

title

KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. (English)

1 reference

29 May 2018

1 reference

5

Pierre Hainaut

1 reference

29 May 2018

Alexis B Cortot

1

1 reference

29 May 2018

Antoine Italiano

series ordinal

2

1 reference

29 May 2018

Fanny Burel-Vandenbos

series ordinal

3

1 reference

29 May 2018

Ghyslaine Martel-Planche

series ordinal

4

1 reference

29 May 2018

language of work or name

English

0 references

publication date

1 June 2010

1 reference

29 May 2018

published in

Cancer

1 reference

29 May 2018

volume

116

1 reference

29 May 2018

issue

11

1 reference

29 May 2018

page(s)

2682-2687

1 reference

29 May 2018

Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Human tumor cell heterogeneity and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

TP53andKRAS2Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Frequent EGFR mutations in brain metastases of lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25014

7 January 2021

Identifiers

DOI

10.1002/CNCR.25014

1 reference

29 May 2018

1 reference

29 May 2018